Scott G Williams
Overview
Explore the profile of Scott G Williams including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
95
Citations
2984
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eapen R, Williams S, MacDonald S, Keam S, Lawrentschuk N, Au L, et al.
Nat Rev Urol
. 2024 Aug;
21(11):676-686.
PMID: 39112733
High-risk localized prostate cancer remains a lethal disease with high rates of recurrence, metastases and death, despite attempts at curative local treatment including surgery. Disease recurrence is thought to be...
2.
Sartor O, Karrison T, Sandler H, Gomella L, Amin M, Purdy J, et al.
Eur Urol
. 2024 Jun;
86(3):289-290.
PMID: 38897867
Background: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer. Objective: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of...
3.
Werner J, Albrecht J, Capaldi V, Jain S, Sun X, Mukherjee P, et al.
Neurology
. 2024 Mar;
102(8):e209269.
PMID: 38547447
Background And Objectives: Insomnia affects about one-third of patients with traumatic brain injury and is associated with worsened outcomes after injury. We hypothesized that higher levels of plasma neuroinflammation biomarkers...
4.
Stein M, Kalff V, Williams S, Murphy D, Colman P, Hofman M
Endocr Oncol
. 2024 Feb;
4(1):e230015.
PMID: 38313829
Objectives: The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, reduces human prostate cancer incidence, and similar GLP-1 receptor agonists reduce proliferation and growth of prostate cancer cell lines. Primary human prostate...
5.
Zhao Y, Haworth A, Reynolds H, Williams S, Finnegan R, Rowshanfarzad P, et al.
Med Phys
. 2024 Jan;
51(5):3766-3781.
PMID: 38224317
Background: Escalation of prescribed dose in prostate cancer (PCa) radiotherapy enables improvement in tumor control at the expense of increased toxicity. Opportunities for reduction of treatment toxicity may emerge if...
6.
Hofman M, Emmett L, Sandhu S, Iravani A, Buteau J, Joshua A, et al.
Lancet Oncol
. 2023 Dec;
25(1):99-107.
PMID: 38043558
Background: The TheraP study reported improved prostate-specific antigen responses with lutetium-177 [Lu]Lu-PSMA-617 versus cabazitaxel in men with metastatic castration-resistant prostate cancer progressing after docetaxel. In this Article, we report the...
7.
Wickwire E, Collen J, Capaldi V, Williams S, Assefa S, Adornetti J, et al.
JMIR Form Res
. 2023 Nov;
7:e47356.
PMID: 37971788
Background: Sleep problems are common and costly in the US military. Yet, within the military health system, there is a gross shortage of trained specialist providers to address sleep problems....
8.
Eapen R, Buteau J, Jackson P, Mitchell C, Oon S, Alghazo O, et al.
Eur Urol
. 2023 Oct;
85(3):217-226.
PMID: 37891072
Background: High-risk localised prostate cancer (HRCaP) has high rates of biochemical recurrence; [Lu]Lu-PSMA-617 is effective in men with advanced prostate cancer. Objective: To investigate the dosimetry, safety, and efficacy of...
9.
Wickwire E, Albrecht J, Capaldi 2nd V, Jain S, Gardner R, Smith M, et al.
J Neurotrauma
. 2023 Jul;
PMID: 37463057
We previously described five trajectories of insomnia (each defined by a distinct pattern of insomnia severity over 12 months following traumatic brain injury [TBI]). Our objective in the present study...
10.
Roberts M, Hruby G, Kneebone A, Martin J, Williams S, Frydenberg M, et al.
BJU Int
. 2023 Jun;
132(2):146-148.
PMID: 37303121
No abstract available.